CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma

Inclusion Criteria: * Documented informed consent of the subject and/or legally authorized representative. * Agreement to allow the use of archival tissue from diagnostic tumor biopsies. * Age 18 years and older. * ECOG status of 0 or 1. * Life expectancy ≥12 weeks. * Subject has a prior histologically confirmed diagnosis of a grade 4 glioblastoma multiforme (GBM) or a prior histologically confirmed diagnosis of a grade 2 or 3 malignant glioma and now has radiographic progression consistent with a grade 4 GBM (IDH wild type), grade 4 diffuse astrocytoma (IDH mutant), or has a unifocal relapse of GBM. * Relapsed disease: radiographic evidence of recurrence/progression of measurable disease after standard therapy and ≥ 12 weeks after completion of front-line radiation therapy. * Confirmed MMP2+ tumor expression by IHC (≥20% moderate/high MMP2 score \[2+ or 3+\]). * Adequate venous access to perform leukapheresis. * No known contraindications to leukapheresis or steroids. * In-range baseline laboratory values for WBC (\>2000/dL \[or ANC ≥1000/mm\^3\]), platelets (≥75000/mm\^3), total bilirubin (≤1.5xULN), AST (≤2.5xULN), ALT (≤2.5xULN), serum creatinine (≤1.5xmg/dL), and oxygen saturation (≥95% on room air) * Seronegative for human immunodeficiency virus (HIV) by antigen/antibody (Ag/Ab) testing. * Seronegative for hepatitis B and/or hepatitis C virus. * Women of childbearing potential must have a negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required. * Agreement by women AND men of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of CHM-1101. (Childbearing potential is defined as not being surgically sterilized (women and men) or, for women, having not been free from menses for \> 1 year.) Exclusion Criteria: * Within 3 months of having received prior bevacizumab therapy at the time of enrollment. * Not yet recovered from toxicities of prior therapy. * Uncontrolled seizure activity and/or clinically evident progressive encephalopathy. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent. * Clinically significant uncontrolled illness. * Active infection requiring antibiotics. * Known history of HIV or hepatitis B or hepatitis C infection. * Other active malignancy. * Women only-pregnant or breastfeeding. * Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures. * Prospective subjects who, in the opinion of the Investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).